Experimental ‘gene silencing’ therapy reduces lipoprotein(a), an important risk factor of heart disease, by up to 98%
Published Date: 4/3/2022
Source: sciencedaily.com
Findings from a phase 1 trial show that an experimental 'gene silencing' therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.